 The FDA has approved ADMA Biologics Incs NASDAQ: ADMA expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool to manufacture Intravenous Immune Globulin IVIG. The 4,400-liter IVIG plasma pool scale for BIVIGAM will allow ADMA to expand its manufacturing plants total processing capacity from 400,000 liters to an anticipated peak throughput of up to 600,000 liters. 